Header Logo

Connection

JORGE E CORTES to Patient Dropouts

Back to Details
This is a "connection" page, showing publications JORGE E CORTES has written about Patient Dropouts.
JORGE E CORTES
Connection Strength
0.088
Patient Dropouts
  1. Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor. Cancer. 2011 Feb 01; 117(3):572-80.
    View in: PubMed
    Score: 0.088
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.